Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience.
Saved in:
| Title: | Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience. |
|---|---|
| Authors: | Antonioli, Elisabetta1 (AUTHOR), Staderini, Michela1 (AUTHOR), Pilerci, Sofia1 (AUTHOR), Perfetto, Federico2 (AUTHOR), Cappelli, Francesco2 (AUTHOR), Allinovi, Marco2,3 (AUTHOR), Nozzoli, Chiara4 (AUTHOR), Attucci, Irene1 (AUTHOR), Buzzichelli, Alessandra1 (AUTHOR), Messeri, Maria1 (AUTHOR), Bosi, Alberto1 (AUTHOR) |
| Source: | Leukemia & Lymphoma. Dec2020, Vol. 61 Issue 13, p3255-3258. 4p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
